Credibility assessment of computational models according to ASME V&V40: Application to the Bologna Biomechanical Computed Tomography solution.

ASME V&V40 Fracture risk prediction Hip fracture In silico trial Model credibility VVUQ

Journal

Computer methods and programs in biomedicine
ISSN: 1872-7565
Titre abrégé: Comput Methods Programs Biomed
Pays: Ireland
ID NLM: 8506513

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 27 01 2023
revised: 17 07 2023
accepted: 18 07 2023
medline: 29 8 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

When a computational model aims to be adopted beyond research purposes, e.g. to inform a clinical or regulatory decision, trust must be placed in its predictive accuracy. This practically translates into the need to demonstrate its credibility. In fact, prior to its adoption for regulatory purposes, an in silico methodology should be proven credible enough for the scope. This has become especially relevant as, although evidence of the safety and efficacy of new medical products or interventions has been traditionally provided to the regulator experimentally, i.e., in vivo or ex vivo, recently the idea to inform a regulatory decision in silico has made its way in the regulatory scenario. While a harmonised technical standard is currently missing in the EU regulatory system, in 2018 the ASME issued V&V40-2018, where a risk-based framework to assess the credibility of a computational model through the performance of predefined credibility activities is provided. The credibility framework is here applied to Bologna Biomechanical Computed Tomography (BBCT) solution, which predicts the absolute risk of fracture at the femur for a subject. BBCT has recently been the object of a qualification advice request to the European Medicine Agency. The full implementation of ASME V&V40-2018 framework on BBCT is shown. Starting from BBCT proposed context of use the whole credibility plan is presented and the credibility activities (Verification, Validation, Applicability) described together with the achieved credibility levels. BBCT risk is judged medium, and the credibility levels achieved considered acceptable. The uncertainties intrinsically present in the material properties assignment affected BBCT predictions to the highest extent. This work provides the practical application of the ASME V&V40-2018 risk-based credibility assessment framework, which could be applied to demonstrate model credibility in any field and support future regulatory submissions and foster the adoption of In Silico Trials.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
When a computational model aims to be adopted beyond research purposes, e.g. to inform a clinical or regulatory decision, trust must be placed in its predictive accuracy. This practically translates into the need to demonstrate its credibility. In fact, prior to its adoption for regulatory purposes, an in silico methodology should be proven credible enough for the scope. This has become especially relevant as, although evidence of the safety and efficacy of new medical products or interventions has been traditionally provided to the regulator experimentally, i.e., in vivo or ex vivo, recently the idea to inform a regulatory decision in silico has made its way in the regulatory scenario. While a harmonised technical standard is currently missing in the EU regulatory system, in 2018 the ASME issued V&V40-2018, where a risk-based framework to assess the credibility of a computational model through the performance of predefined credibility activities is provided. The credibility framework is here applied to Bologna Biomechanical Computed Tomography (BBCT) solution, which predicts the absolute risk of fracture at the femur for a subject. BBCT has recently been the object of a qualification advice request to the European Medicine Agency.
METHODS METHODS
The full implementation of ASME V&V40-2018 framework on BBCT is shown. Starting from BBCT proposed context of use the whole credibility plan is presented and the credibility activities (Verification, Validation, Applicability) described together with the achieved credibility levels.
RESULTS RESULTS
BBCT risk is judged medium, and the credibility levels achieved considered acceptable. The uncertainties intrinsically present in the material properties assignment affected BBCT predictions to the highest extent.
CONCLUSIONS CONCLUSIONS
This work provides the practical application of the ASME V&V40-2018 risk-based credibility assessment framework, which could be applied to demonstrate model credibility in any field and support future regulatory submissions and foster the adoption of In Silico Trials.

Identifiants

pubmed: 37523955
pii: S0169-2607(23)00393-0
doi: 10.1016/j.cmpb.2023.107727
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107727

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alessandra Aldieri (A)

PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Italy; Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: alessandra.aldieri@polito.it.

Cristina Curreli (C)

Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Department of Industrial Engineering, Alma Mater Studiorum - University of Bologna, Bologna, Itlay.

Julia Aleksandra Szyszko (JA)

Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Department of Industrial Engineering, Alma Mater Studiorum - University of Bologna, Bologna, Itlay.

Antonino Amedeo La Mattina (AA)

Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Department of Industrial Engineering, Alma Mater Studiorum - University of Bologna, Bologna, Itlay.

Marco Viceconti (M)

Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Department of Industrial Engineering, Alma Mater Studiorum - University of Bologna, Bologna, Itlay.

Articles similaires

Humans Neoplasms Male Female Middle Aged
Humans Meta-Analysis as Topic Sample Size Models, Statistical Computer Simulation
Humans Patient Reported Outcome Measures Neoplasms Electronic Health Records Delivery of Health Care
Humans Retrospective Studies Male Critical Illness Female

Classifications MeSH